Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 358
Filtrar
1.
Medicine (Baltimore) ; 103(8): e37194, 2024 Feb 23.
Artículo en Inglés | MEDLINE | ID: mdl-38394547

RESUMEN

RATIONALE: Pulmonary artery sarcoma (PAS) is a rare malignant tumor primarily originating from the pulmonary artery's intima or subintima. Approximately one-third of cases are classified as undifferentiated type. Its clinical manifestations lack specificity, dyspnea is the main symptom but can also present with chest pain, cough, hemoptysis, and other discomforts, making it prone to misdiagnosis as pulmonary embolism (PE). PATIENT CONCERNS: A 50-year-old woman was admitted to the hospital with "dyspnea for more than 3 months, aggravated for 2 days," and computed tomography pulmonary angiography suggesting "bilateral multiple pulmonary embolisms." DIAGNOSES: The patient was initially misdiagnosed as PE, and was later definitively diagnosed as undifferentiated pleomorphic sarcoma of the pulmonary artery by pathologic biopsy. INTERVENTIONS AND OUTCOMES: The patient was initially treated with anticoagulant therapy, but her dyspnea was not relieved. After that, she underwent positron emission computed tomography (PET-CT) and other investigations, which suggested the possibility of PAS, and then she underwent pulmonary endarterectomy to remove the lesion, which relieved her symptoms and was advised to seek further medical attention from the Department of Oncology and Department of Radiotherapy. LESSONS: PAS can be easily misdiagnosed as PE. If a diagnosis of PE is made, but anticoagulation or even thrombolytic therapy proves ineffective, and there is no presence of PE causative factors such as deep vein thrombosis in the lower extremities, or D-dimer levels are not high, one should be cautious and consider the possibility of PAS.


Asunto(s)
Hipertensión Pulmonar , Neoplasias Pulmonares , Embolia Pulmonar , Sarcoma , Neoplasias de los Tejidos Blandos , Humanos , Femenino , Persona de Mediana Edad , Arteria Pulmonar/diagnóstico por imagen , Arteria Pulmonar/patología , Tomografía Computarizada por Tomografía de Emisión de Positrones , Hipertensión Pulmonar/complicaciones , Embolia Pulmonar/tratamiento farmacológico , Neoplasias Pulmonares/patología , Neoplasias de los Tejidos Blandos/patología , Disnea/etiología , Disnea/patología , Sarcoma/diagnóstico , Sarcoma/terapia , Sarcoma/complicaciones
2.
Artículo en Alemán | MEDLINE | ID: mdl-38412951

RESUMEN

A 7-year-old Icelandic gelding was presented with acute severe dyspnea of one day duration and purulent nasal discharge that had been present for 6 weeks. Clinically, the initial examination focused on severe enlargement of the mandibular and retropharyngeal lymph nodes as well as a mixed dyspnea.The diagnosis of a malignant lymphoma was evident following laboratory diagnostics, endoscopy, and cytological examination of a fine needle aspiration of a mandibular lymph node. The gelding was euthanized due to the poor prognosis and a significantly disturbed general condition. Pathohistological examination revealed a multicentric T-cell-rich B-cell lymphoma.


Asunto(s)
Enfermedades de los Caballos , Linfoma de Células B , Masculino , Animales , Caballos , Islandia , Linfocitos T/patología , Linfoma de Células B/diagnóstico , Linfoma de Células B/veterinaria , Linfoma de Células B/patología , Biopsia con Aguja Fina/veterinaria , Ganglios Linfáticos/patología , Disnea/patología , Disnea/veterinaria , Enfermedades de los Caballos/diagnóstico
3.
Respirar (Ciudad Autón. B. Aires) ; 15(2): 88-93, jun2023.
Artículo en Español | LILACS | ID: biblio-1437542

RESUMEN

Introducción: la enfermedad pulmonar obstructiva crónica (EPOC) es un trastorno res-piratorio caracterizado por síntomas clínicos y compromiso funcional que afecta la ca-pacidad aeróbica limitando las actividades cotidianas y la calidad de vida. La prueba de caminata de 6 minutos (C6M) es una prueba sencilla y de bajo costo que evalúa la capa-cidad de los pacientes para realizar sus actividades cotidianas. Objetivo: evaluar la re-lación entre la capacidad aeróbica medida por la distancia recorrida en la C6M y el se-xo, edad, disnea y comorbilidades cardiometabólicas en pacientes con EPOC. Material y métodos: estudio de corte transversal, descriptivo, basado en pruebas de caminatas de 6 minutos (C6M) realizadas en pacientes con EPOC. Resultados: se evaluaron 101 pacientes, hombres (63,4%), con una edad promedio de 74,1±8,7 años. Al correlacionar C6M con otras variables se encontraron diferencias estadísticamente significativas. La distancia media recorrida fue mayor en hombres que en mujeres (DM: 58,3 metros, IC 95%; 16 - 100,6, p=0,007). Los pacientes < 75 años, sin comorbilidades y disnea < 2 tu-vieron mejor desempeño en la C6M que los > 75 años (DM; 62,012 metros IC 95% 21,5 - 102,4, p=0,003), con comorbilidades (DM: 42,2 metros, IC 95%, 0.003 - 84,4; p=0,050) y disnea ≥ 2 (DM: 65,8 IC 95% 23,9 - 107,6, p=0,002). Conclusiones: el sexo femenino, la presencia de comorbilidad cardiovascular y metabólica, y la edad se asocian con dis-minución en la capacidad física aeróbica y funcional en los pacientes con EPOC. (AU)


Introduction: chronic obstructive pulmonary disease (COPD) is a respiratory disorder characterized by clinical symptoms and functional impairment that affects aerobic capacity, limiting daily activities and quality of life. The 6-minute walk test (C6M) is a simple, low-cost test that assesses a patient's ability to perform their daily activities. Objective: to evaluate the relationship between aerobic capacity measured by the distance covered in the C6M and gender, age, dyspnea and cardiometabolic comorbidities in patients with COPD. Materials and methods: cross-sectional, descriptive study, based on 6-minute walk tests (C6M) performed in patients with COPD. Results: 101 male patients (63.4%), with a mean age of 74.1 ± 8.7 years, were evaluated. When correlating C6M with other variables, statistically significant differences were found. The mean distance traveled was greater in men than in women (MD: 58.3 meters, 95% CI: 16 - 100.6, p=0.007). Patients <75 years old, without comorbidities and dyspnea <2 had better performance in the C6M than those >75 years old (MD; 62 meters CI 95% 21.5 - 102.4, p=0.003), with comorbidities (MD: 42.2 meters, 95% CI, 0.003 - 84.4; p=0.050) and dyspnea ≥ 2 (MD: 65.8, 95% CI 23.9 - 107.6, p=0.002). Conclusions: female sex, the presence of cardiovascular and metabolic comorbidity, and age are associated with decreased aerobic and functional physical capacity in patients with COPD. (AU)


Asunto(s)
Humanos , Masculino , Femenino , Anciano , Anciano de 80 o más Años , Enfermedad Pulmonar Obstructiva Crónica/patología , Disnea/patología , Prueba de Paso/métodos , Calidad de Vida , Comorbilidad , Colombia , Grupos de Edad
4.
Thorac Cancer ; 14(19): 1894-1898, 2023 07.
Artículo en Inglés | MEDLINE | ID: mdl-37201911

RESUMEN

A 50-year-old Japanese woman with advanced breast cancer presented with productive cough and dyspnea while she was receiving a sixth cycle of chemotherapy including atezolizumab. Chest computed tomography revealed bronchiolitis and transbronchial lung cryobiopsy revealed eosinophilic bronchiolitis. Corticosteroid therapy successfully resolved her symptoms. Eosinophilic bronchiolitis is a rare but important immune-related adverse event; herein, we discuss its diagnosis and possible pathophysiology.


Asunto(s)
Bronquiolitis , Inhibidores de Puntos de Control Inmunológico , Femenino , Humanos , Persona de Mediana Edad , Inhibidores de Puntos de Control Inmunológico/efectos adversos , Bronquiolitis/tratamiento farmacológico , Pulmón/patología , Disnea/patología , Tos/patología
5.
BMJ Case Rep ; 15(8)2022 Aug 09.
Artículo en Inglés | MEDLINE | ID: mdl-35944942

RESUMEN

Primary adenoid cystic carcinoma (ACC) of the trachea is a rare entity, with a 5-year survival between 50% and 80% for resectable cases and 30% in case of unresectable disease. We report a case of a primary ACC on a woman in her 70s that presented with a drawn-out history of dyspnoea. She was diagnosed with an unresectable obstructive tumour of the trachea, which required the placement of a Y-shaped stent. The patient underwent concomitant chemoradiotherapy, with partial response, and is still in follow-up, without evidence of disease progression.


Asunto(s)
Carcinoma Adenoide Quístico , Neoplasias de la Tráquea , Carcinoma Adenoide Quístico/diagnóstico , Carcinoma Adenoide Quístico/diagnóstico por imagen , Disnea/etiología , Disnea/patología , Femenino , Humanos , Tráquea/diagnóstico por imagen , Tráquea/patología , Neoplasias de la Tráquea/diagnóstico , Neoplasias de la Tráquea/diagnóstico por imagen
6.
Zhonghua Er Ke Za Zhi ; 60(9): 930-934, 2022 Sep 02.
Artículo en Chino | MEDLINE | ID: mdl-36038304

RESUMEN

Objective: To analyze the clinical characteristics and prognosis of 6 children with idiopathic interstitial pneumonia (IIP). Methods: This retrospective study analyzed the clinical manifestations, examinations, treatment and prognosis of 6 children with IIP who were hospitalized in Children's Hospital of Nanjing Medical University from January 2015 to March 2020. Results: Of the 6 children, 2 were males and 4 were females, aged 4.8 to10.6 years. All children had a subacute onset, and presented with cough, shortness of breath and cyanosis. The lung high-resolution CT (HRCT) showed diffuse patchiness in bilateral lung fields in all the children and reticular pattern in 2 cases. Pulmonary function test found moderate to severe mixed defect in 5 children. Lung biopsy was performed in 4 children. All of the 6 children were treated with systemic glucocorticoids, of whom 2 cases had additional inhaled glucocorticoids. Four children were finally diagnosed as cryptogenic organizing pneumonia (COP), whose lung HRCT return to normal in 1-11 months. Two children were finally diagnosed as nonspecific interstitial pneumonia (NSIP), and had long-term residual fibrosis on lung HRCT. The 6 children were followed up for 1 year to 6 years and 5 months after discontinuation of systemic glucocorticoids, and all had no recurrence. Conclusions: The clinical characteristics of IIP in children are subacute onset presented with cough, shortness of breath, cyanosis and diffuse patchiness in bilateral lungs on HRCT. The common subtypes of IIP in children are COP and NSIP. Systemic glucocorticoid is effective for IIP in children and there is a good prognosis overall.


Asunto(s)
Neumonía en Organización Criptogénica , Neumonías Intersticiales Idiopáticas , Niño , Tos/etiología , Cianosis/patología , Disnea/patología , Femenino , Glucocorticoides/uso terapéutico , Humanos , Neumonías Intersticiales Idiopáticas/diagnóstico , Neumonías Intersticiales Idiopáticas/patología , Pulmón/patología , Masculino , Estudios Retrospectivos
7.
Intern Med ; 61(18): 2759-2764, 2022 Sep 15.
Artículo en Inglés | MEDLINE | ID: mdl-35249917

RESUMEN

Idiopathic obliterative bronchiolitis (OB) is a rare disease that usually requires a surgical lung biopsy. A 25-year-old woman with progressive exertional dyspnea for several months showed a severe mixed restrictive and obstructive pattern on spirometry. Chest computed tomography showed a mosaic pattern, and pulmonary ventilation-perfusion scintigraphy showed a matched defect. The bronchoscopic specimens obtained from both the alveolar and bronchiolar regions of the predicted lesion area contributed to the diagnosis of OB. She had no underlying causes of secondary OB, and she was diagnosed with idiopathic OB. Since lung transplantation was indicated, she was referred to a lung transplantation-certified hospital.


Asunto(s)
Bronquiolitis Obliterante , Trasplante de Pulmón , Adulto , Biopsia/métodos , Bronquiolitis Obliterante/diagnóstico por imagen , Bronquiolitis Obliterante/patología , Disnea/patología , Femenino , Humanos , Pulmón/diagnóstico por imagen , Pulmón/patología
8.
PLoS One ; 17(2): e0263922, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-35167608

RESUMEN

IMPORTANCE: When hospitals are at capacity, accurate deterioration indices could help identify low-risk patients as potential candidates for home care programs and alleviate hospital strain. To date, many existing deterioration indices are based entirely on structured data from the electronic health record (EHR) and ignore potentially useful information from other sources. OBJECTIVE: To improve the accuracy of existing deterioration indices by incorporating unstructured imaging data from chest radiographs. DESIGN, SETTING, AND PARTICIPANTS: Machine learning models were trained to predict deterioration of patients hospitalized with acute dyspnea using existing deterioration index scores and chest radiographs. Models were trained on hospitalized patients without coronavirus disease 2019 (COVID-19) and then subsequently tested on patients with COVID-19 between January 2020 and December 2020 at a single tertiary care center who had at least one radiograph taken within 48 hours of hospital admission. MAIN OUTCOMES AND MEASURES: Patient deterioration was defined as the need for invasive or non-invasive mechanical ventilation, heated high flow nasal cannula, IV vasopressor administration or in-hospital mortality at any time following admission. The EPIC deterioration index was augmented with unstructured data from chest radiographs to predict risk of deterioration. We compared discriminative performance of the models with and without incorporating chest radiographs using area under the receiver operating curve (AUROC), focusing on comparing the fraction and total patients identified as low risk at different negative predictive values (NPV). RESULTS: Data from 6278 hospitalizations were analyzed, including 5562 hospitalizations without COVID-19 (training cohort) and 716 with COVID-19 (216 in validation, 500 in held-out test cohort). At a NPV of 0.95, the best-performing image-augmented deterioration index identified 49 more (9.8%) individuals as low-risk compared to the deterioration index based on clinical data alone in the first 48 hours of admission. At a NPV of 0.9, the EPIC image-augmented deterioration index identified 26 more individuals (5.2%) as low-risk compared to the deterioration index based on clinical data alone in the first 48 hours of admission. CONCLUSION AND RELEVANCE: Augmenting existing deterioration indices with chest radiographs results in better identification of low-risk patients. The model augmentation strategy could be used in the future to incorporate other forms of unstructured data into existing disease models.


Asunto(s)
Deterioro Clínico , Tórax/diagnóstico por imagen , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , COVID-19/patología , COVID-19/virología , Disnea/patología , Femenino , Hospitalización , Humanos , Aprendizaje Automático , Masculino , Persona de Mediana Edad , Curva ROC , Respiración Artificial , Estudios Retrospectivos , Factores de Riesgo , SARS-CoV-2/aislamiento & purificación , Adulto Joven
9.
PLoS One ; 16(9): e0256480, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34473738

RESUMEN

BACKGROUND: The prevalence of pulmonary embolism (PE) in the acute exacerbation of chronic obstructive pulmonary disease (AE-COPD) is highly controversial. We conducted a systematic review and meta-analysis to summarize the epidemiology and characteristics of PE with AE-COPD for current studies. METHODS: We searched the PubMed, EMBASE, Cochrane Library and Web of Science databases for studies published prior to October 21, 2020. Pooled proportions with 95% confidence intervals (95% CIs) were calculated using a random effects model. Odds ratios (ORs) and mean differences (MDs) with 95% confidence intervals were used as effect measures for dichotomous and continuous variables, respectively. RESULTS: A total of 17 studies involving 3170 patients were included. The prevalence of PE and deep vein thrombosis (DVT) in AE-COPD patients was 17.2% (95% CI: 13.4%-21.3%) and 7.1% (95% CI: 3.7%-11.4%%), respectively. Dyspnea (OR = 6.77, 95% CI: 1.97-23.22), pleuritic chest pain (OR = 3.25, 95% CI: 2.06-5.12), lower limb asymmetry or edema (OR = 2.46, 95% CI:1.51-4.00), higher heart rates (MD = 20.51, 95% CI: 4.95-36.08), longer hospital stays (MD = 3.66, 95% CI: 3.01-4.31) were associated with the PE in the AE-COPD patients. Levels of D-dimer (MD = 1.51, 95% CI: 0.80-2.23), WBC counts (MD = 1.42, 95% CI: 0.14-2.70) were significantly higher and levels of PaO2 was lower (MD = -17.20, 95% CI: -33.94- -0.45, P<0.05) in the AE-COPD with PE group. The AE-COPD with PE group had increased risk of fatal outcome than the AE-COPD group (OR = 2.23, 95% CI: 1.43-3.50). CONCLUSIONS: The prevalence of PE during AE-COPD varies considerably among the studies. AE-COPD patients with PE experienced an increased risk of death, especially among the ICU patients. Understanding the potential risk factors for PE may help clinicians identify AE-COPD patients at increased risk of PE. PROSPERO REGISTRATION NUMBER: CRD42021226568.


Asunto(s)
Dolor en el Pecho/epidemiología , Disnea/epidemiología , Enfermedad Pulmonar Obstructiva Crónica/epidemiología , Edema Pulmonar/epidemiología , Embolia Pulmonar/epidemiología , Trombosis de la Vena/epidemiología , Enfermedad Aguda , Biomarcadores/sangre , Dolor en el Pecho/patología , Disnea/patología , Productos de Degradación de Fibrina-Fibrinógeno/metabolismo , Humanos , Tiempo de Internación/estadística & datos numéricos , Oportunidad Relativa , Prevalencia , Enfermedad Pulmonar Obstructiva Crónica/patología , Edema Pulmonar/patología , Embolia Pulmonar/patología , Factores de Riesgo , Trombosis de la Vena/patología
10.
Rev Med Virol ; 31(6): e2288, 2021 11.
Artículo en Inglés | MEDLINE | ID: mdl-34472152

RESUMEN

SARS Coronavirus-2 is one of the most widespread viruses globally during the 21st century, whose severity and ability to cause severe pneumonia and death vary. We performed a comprehensive systematic review of all studies that met our standardised criteria and then extracted data on the age, symptoms, and different treatments of Covid-19 patients and the prognosis of this disease during follow-up. Cases in this study were divided according to severity and death status and meta-analysed separately using raw mean and single proportion methods. We included 171 complete studies including 62,909 confirmed cases of Covid-19, of which 148 studies were meta-analysed. Symptoms clearly emerged in an escalating manner from mild-moderate symptoms, pneumonia, severe-critical to the group of non-survivors. Hypertension (Pooled proportion (PP): 0.48 [95% Confident interval (CI): 0.35-0.61]), diabetes (PP: 0.23 [95% CI: 0.16-0.33]) and smoking (PP: 0.12 [95% CI: 0.03-0.38]) were highest regarding pre-infection comorbidities in the non-survivor group. While acute respiratory distress syndrome (PP: 0.49 [95% CI: 0.29-0.78]), (PP: 0.63 [95% CI: 0.34-0.97]) remained one of the most common complications in the severe and death group respectively. Bilateral ground-glass opacification (PP: 0.68 [95% CI: 0.59-0.75]) was the most visible radiological image. The mortality rates estimated (PP: 0.11 [95% CI: 0.06-0.19]), (PP: 0.03 [95% CI: 0.01-0.05]), and (PP: 0.01 [95% CI: 0-0.3]) in severe-critical, pneumonia and mild-moderate groups respectively. This study can serve as a high evidence guideline for different clinical presentations of Covid-19, graded from mild to severe, and for special forms like pneumonia and death groups.


Asunto(s)
COVID-19/patología , Tos/patología , Disnea/patología , Fatiga/patología , Fiebre/patología , SARS-CoV-2/patogenicidad , Antivirales/uso terapéutico , COVID-19/mortalidad , COVID-19/virología , Comorbilidad , Tos/tratamiento farmacológico , Tos/mortalidad , Tos/virología , Diabetes Mellitus/diagnóstico , Diabetes Mellitus/fisiopatología , Disnea/tratamiento farmacológico , Disnea/mortalidad , Disnea/virología , Fatiga/tratamiento farmacológico , Fatiga/mortalidad , Fatiga/virología , Fiebre/tratamiento farmacológico , Fiebre/mortalidad , Fiebre/virología , Humanos , Hipertensión/diagnóstico , Hipertensión/fisiopatología , Factores Inmunológicos/uso terapéutico , Pronóstico , Síndrome de Dificultad Respiratoria/diagnóstico , Síndrome de Dificultad Respiratoria/fisiopatología , Índice de Severidad de la Enfermedad , Fumar/fisiopatología , Análisis de Supervivencia , Tratamiento Farmacológico de COVID-19
12.
PLoS One ; 16(7): e0255141, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34297774

RESUMEN

The natural history of COVID-19 and predictors of mortality in older adults need to be investigated to inform clinical operations and healthcare policy planning. A retrospective study took place in 80 long-term nursing homes in Catalonia, Spain collecting data from March 1st to May 31st, 2020. Demographic and clinical data from 2,092 RT-PCR confirmed cases of SARS-CoV-2 infection were registered, including structural characteristics of the facilities. Descriptive statistics to describe the demographic, clinical, and molecular characteristics of our sample were prepared, both overall and by their symptomatology was performed and an analysis of statistically significant bivariate differences and constructions of a logistic regression model were carried out to assess the relationship between variables. The incidence of the infection was 28%. 71% of the residents showed symptoms. Five major symptoms included: fever, dyspnea, dry cough, asthenia and diarrhea. Fever and dyspnea were by far the most frequent (50% and 28%, respectively). The presentation was predominantly acute and symptomatology persisted from days to weeks (mean 9.1 days, SD = 10,9). 16% of residents had confirmed pneumonia and 22% required hospitalization. The accumulated mortality rate was 21.75% (86% concentrated during the first 28 days at onset). A multivariate logistic regression analysis showed a positive predictive value for mortality for some variables such as age, pneumonia, fever, dyspnea, stupor refusal to oral intake and dementia (p<0.01 for all variables). Results suggest that density in the nursing homes did not account for differences in the incidence of the infection within the facilities. This study provides insights into the natural history of the disease in older adults with high dependency living in long-term nursing homes during the first pandemic wave of March-May 2020 in the region of Catalonia, and suggests that some comorbidities and symptoms have a strong predictive value for mortality.


Asunto(s)
COVID-19 , Disnea , Fiebre , Casas de Salud , SARS-CoV-2 , Anciano , Anciano de 80 o más Años , COVID-19/mortalidad , COVID-19/patología , COVID-19/fisiopatología , Comorbilidad , Disnea/mortalidad , Disnea/patología , Disnea/fisiopatología , Femenino , Fiebre/mortalidad , Fiebre/patología , Fiebre/fisiopatología , Humanos , Incidencia , Masculino , Estudios Retrospectivos , España/epidemiología
13.
J Enzyme Inhib Med Chem ; 36(1): 1230-1235, 2021 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-34074197

RESUMEN

The ongoing Covid-19 is a contagious disease, and it is characterised by different symptoms such as fever, cough, and shortness of breath. Rising concerns about Covid-19 have severely affected the healthcare system in all countries as the Covid-19 outbreak has developed at a rapid rate all around the globe. Intriguing, a clinically used drug, acetazolamide (a specific inhibitor of carbonic anhydrase, CA, EC 4.2.1.1), is used to treat high-altitude pulmonary oedema (HAPE), showing a high degree of clinical similarities with the pulmonary disease caused by Covid-19. In this context, this preliminary study aims to provide insights into some factors affecting the Covid-19 patients, such as hypoxaemia, hypoxia as well as the blood CA activity. We hypothesise that patients with Covid-19 problems could show a dysregulated acid-base status influenced by CA activity. These preliminary results suggest that the use of CA inhibitors as a pharmacological treatment for Covid-19 may be beneficial.


Asunto(s)
Acetazolamida/uso terapéutico , Antivirales/uso terapéutico , Tratamiento Farmacológico de COVID-19 , Inhibidores de Anhidrasa Carbónica/uso terapéutico , Anhidrasas Carbónicas/sangre , Equilibrio Ácido-Base/efectos de los fármacos , Mal de Altura/sangre , Mal de Altura/tratamiento farmacológico , Anticonvulsivantes/uso terapéutico , Bicarbonatos/sangre , COVID-19/sangre , COVID-19/diagnóstico por imagen , COVID-19/virología , Dióxido de Carbono/sangre , Tos/sangre , Tos/tratamiento farmacológico , Tos/patología , Tos/virología , Reposicionamiento de Medicamentos , Disnea/sangre , Disnea/tratamiento farmacológico , Disnea/patología , Disnea/virología , Fiebre/sangre , Fiebre/tratamiento farmacológico , Fiebre/patología , Fiebre/virología , Humanos , Concentración de Iones de Hidrógeno , Hipertensión Pulmonar/sangre , Hipertensión Pulmonar/tratamiento farmacológico , Hipoxia/sangre , Hipoxia/tratamiento farmacológico , Hipoxia/patología , Hipoxia/virología , Oximetría , Proyectos de Investigación , SARS-CoV-2/patogenicidad , SARS-CoV-2/fisiología , Índice de Severidad de la Enfermedad , Tomografía Computarizada por Rayos X
14.
PLoS One ; 16(3): e0248603, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-33770113

RESUMEN

INTRODUCTION: Patients at intermediate-high risk of developing a pulmonary embolism (PE) are very likely to experience adverse outcomes, such as cardiovascular instability and death. The role of thrombolytic therapy in intermediate-high-risk PE remains controversial. OBJECTIVES: This study aimed to determine the efficacy and safety of low-dose urokinase (UK) thrombolytic therapy for intermediate-high-risk PE. PATIENTS AND METHODS: This retrospective study included 81 consecutive patients with intermediate-high-risk PE from two centers. Patients received low-dose UK or low-molecular-weight heparin (anticoagulant therapy group). The efficacy outcomes were mortality, computed tomography pulmonary angiography (CTPA)-confirmed absorption, and dyspnea. Safety was assessed as the incidence of bleedings. RESULTS: The in-hospital mortality, 9-month mortality, and long-term mortality at the last follow-up were comparable for the low-dose UK group and the anticoagulant therapy group (6.45% vs. 0%, p = 0.144, 9.68% vs. 8.16%, p = 0.815, and 12.90% vs. 12.24%, p = 0.931, respectively). CTPA-confirmed absorption at one month after admission was higher in the low-dose UK group than in the anticoagulant therapy group (p = 0.016). The incidences of short-term dyspnea at discharge and long-term dyspnea at the last follow-up were lower in the low-dose UK group than in the anticoagulant therapy group (27.59% vs. 52%, p = 0.035, 33.33% vs. 58.14%, p = 0.043, respectively). No major bleeding occurred. The incidence of minor bleeding was not significantly different between the two groups (3.23% vs. 6%, p = 0.974). CONCLUSION: In intermediate-high-risk PE, a low-dose UK might increase CTPA-confirmed absorption and improve short-term and long-term dyspnea without affecting mortality or increasing the bleeding risk.


Asunto(s)
Disnea/tratamiento farmacológico , Embolia Pulmonar/tratamiento farmacológico , Terapia Trombolítica , Activador de Plasminógeno de Tipo Uroquinasa/administración & dosificación , Adulto , Anciano , Anciano de 80 o más Años , Anticoagulantes/administración & dosificación , Estudios de Cohortes , Angiografía por Tomografía Computarizada , Disnea/complicaciones , Disnea/diagnóstico por imagen , Disnea/patología , Femenino , Hemodinámica , Hemorragia/diagnóstico por imagen , Hemorragia/tratamiento farmacológico , Hemorragia/patología , Heparina de Bajo-Peso-Molecular/administración & dosificación , Humanos , Masculino , Persona de Mediana Edad , Embolia Pulmonar/diagnóstico por imagen , Embolia Pulmonar/patología , Factores de Riesgo , Activador de Plasminógeno de Tipo Uroquinasa/efectos adversos
15.
Sci Rep ; 11(1): 6874, 2021 03 25.
Artículo en Inglés | MEDLINE | ID: mdl-33767311

RESUMEN

Dyspnoea is a cardinal symptom of fibrotic interstitial lung disease (ILD), with a lack of proven effective therapies. With emerging evidence of the role of facial and nasal airflow for relieving breathlessness, this pilot study was conducted to examine the feasibility of conducting a clinical trial of a handheld fan (HHF) for dyspnoea management in patients with fibrotic ILD. In this mixed-methods, randomised, assessor-blinded, controlled trial, 30 participants with fibrotic ILD who were dyspnoeic with a modified Medical Research Council Dyspnoea grade ≥ 2 were randomised to a HHF for symptom control or no intervention for 2 weeks. Primary outcomes were trial feasibility, change in Dyspnoea-12 scores at Week 2, and participants' perspectives on using a HHF for dyspnoea management. Study recruitment was completed within nine months at a single site. Successful assessor blinding was achieved in the fan group [Bang's Blinding Index - 0.08 (95% CI - 0.45, 0.30)] but not the control group [0.47 (0.12, 0.81)]. There were no significant between-group differences for the change in Dyspnoea-12 or secondary efficacy outcomes. During qualitative interviews, participants reported that using the HHF relieved breathlessness and provided relaxation, despite initial scepticism about its therapeutic benefit. Oxygen-experienced participants described the HHF being easier to use, but not as effective for symptomatic relief, compared to oxygen therapy. Our results confirmed the feasibility of a clinical trial of a HHF in fibrotic ILD. There was a high level of patient acceptance of a HHF for managing dyspnoea, with patients reporting both symptomatic benefits and ease of use.


Asunto(s)
Disnea/terapia , Enfermedades Pulmonares Intersticiales/complicaciones , Terapia por Inhalación de Oxígeno/instrumentación , Terapia por Inhalación de Oxígeno/métodos , Calidad de Vida , Automanejo/métodos , Anciano , Estudios de Casos y Controles , Disnea/etiología , Disnea/patología , Femenino , Humanos , Masculino , Proyectos Piloto , Método Simple Ciego
16.
Eur J Clin Microbiol Infect Dis ; 40(7): 1427-1431, 2021 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-33532945

RESUMEN

Polymerase chain reaction (PCR)-based diagnostics for Mycoplasma pneumoniae (M. pneumoniae) from the respiratory tract has become widely available, but the interpretation of the results remains unclear. M. pneumoniae has been suggested to cause mainly mild and self-limiting infections or asymptomatic carriage. However, systematic analyses of the association between PCR results and clinical findings are scarce. This study aimed to clarify the clinical features of PCR-positive M. pneumoniae infections in a hospital setting. We reviewed 103 PCR-positive patients cared for in a university hospital during a 3-year period. Data on age, sex, health condition, acute symptoms, other pathogens found, laboratory and X-ray results and treatments were collected. Over 85% of the patients had a triad of typical symptoms: fever, cough and shortness of breath. Symptoms in the upper respiratory tract were rare. In 91% of the cases, M. pneumoniae was the only pathogen found. The highest incidence was found in the age group of 30-40 years, and 68% of the patients did not have any underlying diseases. Most patients were initially empirically treated with beta-lactam antibiotics and needed 2-4 changes in their treatment. Only 6% were discharged without an antibiotic effective against M. pneumoniae. This study shows that M. pneumoniae often led to hospitalisation and that patients needed appropriate antimicrobial treatment to recover. Mixed infections were rare, and situations that could be interpreted as carriage did not occur.


Asunto(s)
Disnea/microbiología , Hospitalización , Mycoplasma pneumoniae , Neumonía por Mycoplasma/microbiología , Neumonía por Mycoplasma/patología , Reacción en Cadena de la Polimerasa , Adulto , Anciano , Anciano de 80 o más Años , Niño , Preescolar , Disnea/patología , Humanos , Lactante , Persona de Mediana Edad , Adulto Joven
17.
Infection ; 49(1): 153-157, 2021 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-32725597

RESUMEN

PURPOSE: The aim of our study was to assess respiratory function at the time of clinical recovery and 6 weeks after discharge in patients surviving to COVID-19 pneumonia. METHODS: Our case series consisted of 13 patients with COVID-19 pneumonia. RESULTS: At the time of clinical recovery, FEV1 (2.07 ± 0.72 L) and FVC (2.25 ± 0.86 L) were lower compared to lower limit of normality (LLN) values (2.56 ± 0.53 L, p = 0.004, and 3.31 ± 0.65 L, p < 0.001, respectively), while FEV1/FVC (0.94 ± 0.07) was higher compared to upper limit of normality (ULN) values (0.89 ± 0.01, p = 0.029). After 6 weeks pulmonary function improved but FVC was still lower than ULN (2.87 ± 0.81, p = 0.014). CONCLUSION: These findings suggest that COVID-19 pneumonia may result in clinically relevant alterations in pulmonary function tests, with a mainly restrictive pattern.


Asunto(s)
COVID-19/fisiopatología , Tos/fisiopatología , Disnea/fisiopatología , Fiebre/fisiopatología , Pulmón/fisiopatología , SARS-CoV-2/patogenicidad , Adulto , Anciano , COVID-19/diagnóstico , COVID-19/patología , COVID-19/virología , Tos/diagnóstico , Tos/patología , Tos/virología , Disnea/diagnóstico , Disnea/patología , Disnea/virología , Femenino , Fiebre/diagnóstico , Fiebre/patología , Fiebre/virología , Humanos , Pulmón/diagnóstico por imagen , Pulmón/patología , Pulmón/virología , Masculino , Persona de Mediana Edad , Pruebas de Función Respiratoria , Espirometría , Tomografía Computarizada por Rayos X
18.
J Med Virol ; 93(3): 1761-1765, 2021 03.
Artículo en Inglés | MEDLINE | ID: mdl-32889755

RESUMEN

To determine the distribution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) respiratory viral loads (VL) during the acute phase of infection and their correlation with clinical presentation and inflammation-related biomarkers. Nasopharyngeal swabs from 453 adult SARS-CoV-2-infected patients from the Department of Infectious Diseases, Besançon, France, were collected at the time of admission or consultation for reverse transcriptase polymerase chain reaction (RT-PCR) analysis. Clinical information and concentrations of biological parameters (C-reactive protein [CRP], fibrinogen, lactate dehydrogenase [LDH], prealbumin) were noticed. Mean respiratory VL homogeneously decreased from 7.2 log10 copies/ml (95% confidence interval [CI]: 6.6-7.8) on the first day of symptoms until 4.6 log10 copies/ml (95% CI: 3.8-5.4) at day 10 (slope = -0.24; R2 = .95). VL were poorly correlated with COVID-19 symptoms and outcome, excepted for dyspnea and anosmia, which were significantly associated with lower VL (p < .05). CRP, fibrinogen, and LDH concentrations significantly increased over the first 10 days (median CRP concentrations from 36.8 mg/L at days 0-1 to 99.5 mg/L at days 8-10; p < .01), whereas prealbumin concentrations tended to decrease. Since SARS-CoV-2 respiratory VL regularly decrease in the acute phase of infection, determining the level of VL may help predicting the onset of virus shedding in a specific patient. However, the role of SARS-CoV-2 VL as a biomarker of severity is limited.


Asunto(s)
Prueba de COVID-19/métodos , COVID-19/diagnóstico , COVID-19/epidemiología , Carga Viral/métodos , Adulto , Anciano , Anciano de 80 o más Años , Anosmia/patología , Proteína C-Reactiva/análisis , Disnea/patología , Femenino , Fibrinógeno/análisis , Francia/epidemiología , Humanos , L-Lactato Deshidrogenasa/sangre , Masculino , Persona de Mediana Edad , Nasofaringe/virología , Prealbúmina/análisis , ARN Viral/análisis , SARS-CoV-2 , Resultado del Tratamiento , Esparcimiento de Virus , Adulto Joven
19.
Biomed Res Int ; 2020: 4357910, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-33145348

RESUMEN

BACKGROUND: Human adenoviruses (HAdVs) are commonly causing respiratory disease. We molecularly genotyped HAdV circulating in Chinese hospitalized children with respiratory infections and summarized the clinical profiles and common inflammatory biomarkers, so as to better determine their associations with disease severity. METHOD: Children with respiratory single HAdV infection cases that occurred from December 2017 to March 2019 were enrolled for a cross-sectional study. Clinical/laboratory features based on the genotypes of respiratory HAdV infection were reviewed for comparative analysis. RESULTS: A total of 84 patients were enrolled, and HAdV types were identified from 82 patients. Species B (HAdV-7, 44%; HAdV-3, 43%, and HAdV-14, 5%) was the most common, followed by C (HAdV-2, 4% and HAdV-1, 1%) and E (HAdV-4, 1%). Severe HAdV infection and HAdV-7 infection groups were associated with significantly longer duration of fever and hospitalized days, higher morbidity of tachypnea/dyspnea, more pleural effusion, more respiratory rales, more frequently required mechanical ventilation, and significantly higher fatality rate. The elevated procalcitonin (PCT) and C-reactive protein (CRP) levels were significantly associated with severe HAdV infection. CONCLUSIONS: HAdV-7 and HAdV-3 were the most common types among children with respiratory adenovirus infection; vaccines against these two genotypes are in urgent need. PCT and CRP are significantly associated with the severity of HAdV infection.


Asunto(s)
Infecciones por Adenoviridae/diagnóstico , Adenovirus Humanos/genética , Proteína C-Reactiva/genética , Disnea/diagnóstico , Derrame Pleural/diagnóstico , Polipéptido alfa Relacionado con Calcitonina/genética , Infecciones del Sistema Respiratorio/diagnóstico , Infecciones por Adenoviridae/mortalidad , Infecciones por Adenoviridae/patología , Infecciones por Adenoviridae/virología , Adenovirus Humanos/clasificación , Adenovirus Humanos/aislamiento & purificación , Adenovirus Humanos/patogenicidad , Adolescente , Biomarcadores/sangre , Proteína C-Reactiva/metabolismo , Niño , Preescolar , Estudios Transversales , Disnea/mortalidad , Disnea/patología , Disnea/virología , Femenino , Expresión Génica , Genotipo , Humanos , Lactante , Tiempo de Internación/estadística & datos numéricos , Masculino , Epidemiología Molecular , Filogenia , Derrame Pleural/mortalidad , Derrame Pleural/patología , Derrame Pleural/virología , Polipéptido alfa Relacionado con Calcitonina/sangre , Respiración Artificial/estadística & datos numéricos , Infecciones del Sistema Respiratorio/mortalidad , Infecciones del Sistema Respiratorio/patología , Infecciones del Sistema Respiratorio/virología , Índice de Severidad de la Enfermedad , Análisis de Supervivencia
20.
J Rehabil Med ; 52(10): jrm00116, 2020 Oct 22.
Artículo en Inglés | MEDLINE | ID: mdl-33043382

RESUMEN

OBJECTIVE: A better understanding of factors influencing breathing weakness in stroke survivors would help in planning rehabilitation therapies. The main objective of this study was to determine whether the location of cerebral infarct is associated with breathing weakness in patients with subacute stroke. DESIGN: Cross-sectional analysis of a prospective cohort. PATIENTS: Consecutive patients admitted to a neurology rehabilitation unit with first-time ischaemic stroke (n?=?170). METHODS: Breathing weakness was defined as >?70% reduction in maximal inspiratory and expiratory pressures (PImax and PEmax, respectively) compared with reference values. Computed tomography and magnetic resonance imaging were used to locate stroke lesions, which were classified as cortical, subcortical, cortico-subcortical, brainstem, or cerebellum. The affected cerebrovascular territory was identified to classify stroke subtype. The association between maximal respiratory pressure and affected brain area was studied using median regression analysis. RESULTS: Breathing weakness was detected in 151 (88.8%) patients. Those with cortical and cortico-subcortical stroke location had the lowest PImax and PEmax values (median 33 cmH2O). This value differed significantly from maximal respiratory pressures of patients with strokes located in the brainstem and the cerebellum, with PImax median differences (?) of 16 cmH2O (95% confidence interval (95% CI) 4.127.9) and 27 cmH2O (95% CI 7.846.2), respectively, and PEmax median differences of 27 cmH2O (95% CI 11.442.7) and 49 cmH2O (95% CI 23.774.3), respectively, both of which remained significant after adjustments. CONCLUSION: The prevalence of breathing weakness was very high in stroke patients admitted to a neurorehabilitation ward, being more severe in cortical or cortico-subcortical stroke.


Asunto(s)
Encéfalo/patología , Infarto Cerebral/patología , Disnea/patología , Respiración , Accidente Cerebrovascular/patología , Anciano , Encéfalo/diagnóstico por imagen , Infarto Cerebral/complicaciones , Infarto Cerebral/diagnóstico por imagen , Estudios de Cohortes , Estudios Transversales , Disnea/diagnóstico por imagen , Disnea/epidemiología , Femenino , Humanos , Masculino , Presiones Respiratorias Máximas , Persona de Mediana Edad , Prevalencia , Estudios Prospectivos , Análisis de Regresión , Accidente Cerebrovascular/complicaciones , Accidente Cerebrovascular/diagnóstico por imagen , Rehabilitación de Accidente Cerebrovascular/estadística & datos numéricos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...